MediNet Group Limited (HKG:8161)
Hong Kong · Delayed Price · Currency is HKD 0.4550
+0.0050 (1.11%)
Jul 21, 2025, 2:38 PM HKT
Intra-Cellular Therapies Revenue
In the fiscal year ending March 31, 2025, MediNet Group had annual revenue of 106.39M HKD, down -8.48%. MediNet Group had revenue of 48.52M in the half year ending March 31, 2025, a decrease of -6.10%.
Revenue
106.39M
Revenue Growth
-8.48%
P/S Ratio
0.18
Revenue / Employee
1.30M
Employees
82
Market Cap
18.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 106.39M | -9.86M | -8.48% |
| Mar 31, 2024 | 116.25M | 5.86M | 5.30% |
| Mar 31, 2023 | 110.39M | -10.68M | -8.82% |
| Mar 31, 2022 | 121.07M | -8.41M | -6.50% |
| Mar 31, 2021 | 129.48M | -15.46M | -10.67% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |